Proscia is rewiring pathology to speed up the development of targeted therapies, accelerate diagnosis, and match more patients with the best ...

Oncimmune, a precision medicine company spun out from the University of Nottingham, has fallen into administration.

Ataraxis AI, the leading AI precision medicine company, today announced its $20.4 million Series A financing led by AIX ...

The company’s impact extends beyond regulatory innovation, contributing significantly to the regional economy by positioning Belfast as a global hub for precision medicine expertise. Through job ...

AI-driven healthcare solutions provider Tempus AI (TEM) has disclosed acquisition of Deep 6 AI, a precision research platform ...

Pharos iBio announced on the 21st that it has signed a memorandum of understanding (MOU) for the development of companion ...

A new precision oncology paper was published in Oncotarget, Volume 16, on March 12, 2025, titled “Worldwide Innovative ...

As part of this Research Topic, we are hosting a webinar and public Q&A featuring Prof. Michael Lutz (Duke University) and Dr. Jean-Marie Bouteiller ...

the leading AI precision medicine company, today announced its $20.4 million Series A financing led by AIX Ventures with participation from Floating Point, Thiel Bio, Founders Fund, Bertelsmann ...

We couldn’t be more excited to back them on this journey.” About Ataraxis AI Ataraxis is an AI precision medicine company transforming patient outcomes through the power of artificial ...